OTTAWA —
After weeks of dose shortages, the federal government says it will still be a few weeks before Canada’s Pfizer deliveries fully ramp up to pre-interruption levels, while Moderna’s next shipment has yet to be confirmed.
Maj.-Gen. Dany Fortin announced Thursday that Canada is expected to receive approximately 70,000 Pfizer-BioNTech doses next week, and that the number of doses coming in the next Moderna shipment slotted for the week of Feb. 22 is expected to be impacted, but how severely remains unclear.
The number of doses Canada’s been able to administer over the last few weeks has been affected in large part by Pfizer significantly reducing the number of doses it has been sending as it scales up its European facilities. However, Moderna — the second and only other currently approved COVID-19 vaccine in Canada — has experienced recent production problems resulting in slightly reduced deliveries to Canada.
This week, Canada received and distributed 79,000 doses of Pfizer-BioNTech to the provinces, and Moderna has sent 180,000 doses to be distributed in the coming days to sites in northern, remote and isolated communities.
Before Pfizer’s delivery delays were announced in January, Canada was planning on receiving up to 367,575 Pfizer-BioNTech doses this week, and this week’s Moderna shipment was supposed to include 230,400 doses.
Fortin said that Pfizer plans to scale up shipments later this month, forecasting shipments of at least 335,000 doses the week of Feb. 15, and 395,000 the last week of February.
Canada was expecting to receive 249,000 Moderna doses in the Feb. 22 shipment, now the government does not expect to receive that amount, “for a number of reasons” which Fortin did not elaborate on.
“I can’t really tell you what the quantity will be, but we do not expect to receive 249,000 at this time,” he said.
“This is a long game,” said Fortin, who is leading the logistics of Canada’s vaccine rollout, in an update.
He is vowing to keep the provinces and territories abreast of the evolving situation.
“I completely understand that it’s making it more difficult for provinces to prepare clinics and prepare the vaccine distribution sites,” said Fortin.
The government continues to state that by the end of March, Canada will meet its target of administering a total of six million vaccine doses, enough to fully immunize three million people, as part of the “Phase 1” vaccine rollout before opening up eligibility to millions more Canadians in the spring.
“Phase 2 of the vaccine rollout, the ramp up, will see a significant increase in vaccine supply across Canada. We’re expecting 20 million doses of authorized vaccines to be available in the April to June timeframe,” Fortin said.
Shortages have left Canada’s front-line vaccine administrators with fewer doses to dole out than they planned for. This resulted in shifting prioritizations to inoculate residents and staff in long-term care homes, and delayed appointments for some front-line health-care workers waiting for either their first or second dose.
TRIED FOR DOMESTIC PRODUCTION: ANAND
Amid the reduced shipments Canada has fallen behind several countries in rolling out its mass vaccination campaign when compared on a per capita basis and the federal Liberals have faced a continued grilling from the opposition parties over their procurement approach and lacking domestic capacity.
In an effort to bolster future domestic production, Prime Minister Justin Trudeau announced earlier this week the federal government had signed a “memorandum of understanding” with U.S.-based Novavax to pursue options to produce its COVID-19 vaccine at a new Montreal facility. However, that site is still under construction and vaccine production there isn’t expected to be able to start until this fall at the earliest.
“Canada likely won’t be producing vaccines here at home until 2022. Now we are learning that Moderna’s scheduled shipments for later this month, are also up in the air. Much of this uncertainty is due to the failure to plan by the Liberal government,” said Conservative Leader Erin O’Toole on Thursday.
Seeking to defend Canada’s position while testifying before a House of Commons committee digging into Canada’s vaccine capacity, Procurement Minister Anita Anand told MPs that her department “proactively and repeatedly approached leading vaccine manufacturers with offers to leverage this domestic capacity and possibility here in Canada.”
However, all of them turned the offer down, citing a desire to make vaccines in existing plants that were shown to be able to manufacture at a global scale.
“We took this issue up with suppliers, at every turn at the negotiating table to discern whether they would come to the table with this possibility of domestic biomanufacturing. The manufacturers reviewed the identified assets here in Canada, and concluded that biomanufacturing capacity in this country at the time of contracting—which was last August and September— was too limited to justify the investment of capital, and expertise to start manufacturing in Canada,” she said.
PLANNING FOR NEW VACCINES
Amid the reduced shipments Canada has fallen behind several countries in rolling out its mass vaccination campaign when compared on a per capita basis and the federal Liberals have faced a continued grilling from the opposition parties over their procurement approach and lacking domestic capacity.
As of Thursday morning, more than 1.1 million doses have arrived in Canada, resulting in nearly 872,000 first doses and 136,000 second doses being administered, according to CTV News’ vaccine tracker.
In total Canada has deals in place securing access to 40 million doses from Pfizer and 40 million doses from Moderna, which should be enough to vaccinate every Canadian who wants to be, by the end of September.
Though, there could be millions more doses on their way to Canada in the near future, if Health Canada grants regulatory approval to either the AstraZeneca or Johnson & Johnson vaccine candidates.
While the precise timing of Health Canada’s anticipated approval of these two vaccine candidates remains uncertain, it’s possible that new authorizations could come before the end of March, while the Phase 1 rollout is still underway.
Fortin said that contingency plans are being put in place to handle the addition of other vaccines into the logistical planning process, stating they are plotting out “multiple scenarios” that factor in seeing provinces able to leverage clinics and pharmacies as options for future vaccine administration sites.
“We have made projections available to provinces with regards to what we expect to see in terms of additional quantities and additional vaccine candidates,” Fortin said.
TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.
The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.
“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.
The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.
But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.
Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.
“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.
“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”
Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.
The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.
In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.
Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.
The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.
The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.
Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.
Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.
It will also re-evaluate its design ranks.
Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.
Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.
This report by The Canadian Press was first published Sept. 13, 2024.
VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.
No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.
About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.
Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.
Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.
A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”
This report by The Canadian Press was first published Sept. 12, 2024.
MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.
The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.
The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.
Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.
On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.
Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.
This report by The Canadian Press was first published Sept. 12, 2024.
